Doubts persist about whether the effects of Celgene's mongersen (also known as GED-0301) in Crohn's disease are real, some of which could be dispelled by an ongoing Phase Ib endoscopy trial. Investors were hoping for more details from an interim glimpse provided this week, and analysts were somewhat divided about how best to read what few tea leaves the company did reveal (see ViewPoints: Celgene investors and analysts left waiting by Crohn's disease drug update).
To better understand the relevance of this week's results and what they might mean for the future development of mongersen, as well to glean more information about what to look for when the detailed data are eventually revealed, we are hosting an expert call with a leading key opinion leader on Thursday (September 15).
Key topics to be discussed include, among other things...whether this week's disclosure adds or removes risk from mongersen's story, putting the new information about endoscopic improvement and response rates into context, and expectations for the detailed data presentation expected later this year.
Ask the expert!
Furthermore, we invite FirstWord Pharma readers to submit their own questions for consideration. Please click here to do so. We can't guarantee that all questions submitted will be asked due to time constraints, but we will do our utmost to cover the important issues relating to the latest peek at clinical results for Celgene’s mongersen.
We endeavour to provide feedback from KOLs as quickly as possible. Interview content will be published for FirstWord Pharma PLUS subscribers to read. To be notified when the interview content is available please click here.
As always, FirstWord would very much like to receive your feedback and suggestions.
To read more KOL Views articles, click here.